Merck and Protillion Partner to Advance Drug Discovery
As the disease progresses and takes different forms, finding medicines and treatments becomes increasingly difficult. Almost all healthcare and pharma companies are on one mission: to develop medicines faster and better. And this race never ends. Entering the race, Protillion Biosciences has announced its collaboration with Merck to accelerate drug discovery.
This partnership with Merck (known as MSD outside the USA and Canada), one of the world’s leading pharma giants, promises advancements in developing medicines, better and faster. The collaboration aims to combine Protillion’s advanced protein engineering technology with Merck’s extensive expertise in the discovery of novel biologic drug candidates.
Protillion Biosciences is known for its high-throughput protein engineering platform. The agreement’s frontend is to work on multiple drug discovery programs. Aiming to identify and design promising drug candidates with the potential to develop into medicines for various diseases.
Mostly, proteins are the key molecules that take their turn to become a drug. Identifying the target lead molecule and its interaction with the host is a huge journey. Clearing clinical trials and getting them to market takes years. But with AI, the first few steps become easy. There are different tools that identify the target molecule from huge datasets worldwide, and pharma giants are investing in AI-powered drug discovery.
Prot-MaPTM, Protillion-owned technology, is the center of this partnership. It facilitates researchers in analyzing and optimizing a large set of protein variants and datasets at the same time. Not only that, but it also provides detailed information, which in turn helps researchers to understand the therapeutic profiles and make better decisions. Unlike traditional methods, this Next-gen approach enables quick selection of potential lead molecules.
The technology may also help researchers create more advanced biologic drugs that can perform specific tasks in the body, like pH-dependent sweeping and target diseases more effectively.
To support the multiple discoveries, Merck has agreed to a commercial payment of more than $510 million. What is Protillion going to do with this? This fund supports research, development, regulatory, and other related procedures. This proves the ability of Protillion’s technology and Merck’s excellence in transforming drug discovery.
Speaking about the collaboration, Juan Alvarez, PhD, Vice President of Discovery Biologics at Merck Research Laboratories, said that Protillion’s platform offers exciting opportunities for discovering new biologic medicines. He added that Merck looks forward to working with Protillion to advance these programs.
For Protillion, this is a major milestone. Using their technology and contributing to the field of medicine quickly and precisely means a lot. This not only adds value to the company but also helps build trust among the global pharmaceutical companies. The recent joining of industry veteran Bob Hollingsworth as Chief Scientific Officer marks Protillion’s growth. It aims to expand the company’s team and improve the infrastructure to support the pipeline.
While it may take years before any resulting medicines reach patients, this collaboration represents another important effort to make drug discovery faster, smarter, and more effective.
